Back to results
US 2015/0147763 A1Published application
Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis
AssigneesGanymed Pharmaceuticals AG, TRON- Translationale Onkologie an der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
InventorsUgur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
Claims20
An antibody or antigen-binding fragment thereof which
- (i) binds to a peptide having the amino acid sequence TEDEVQSYPSKHDYV (SEQ ID NO:
- 5) or EVQSYPSKHDYV (SEQ ID NO:
- 6) and/or
- (ii) binds to claudin 18.2 (CLDN18.2), wherein said antibody or antigen-binding fragment thereof binds to CLDN18.2 by binding at least to an epitope within CLDN18.2 having the amino acid sequence TEDEVQSYPSKHDYV (SEQ ID NO:
- 5) or EVQSYPSKHDYV (SEQ ID NO:
- 6).
3 more elements
An antibody selected from the group consisting of:
- (i) an antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A),
- (ii) an antibody which is a chimerized or humanized form of the antibody under (i),
- (iii) an antibody which has the specificity of the antibody under (i), and
- (iv) an antibody comprising the antigen binding portion or antigen binding site of the antibody under (i), or
- an antigen-binding fragment of the antibody under any one of (i) to (iv).
2 more elements
A hybridoma deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).
Dependencies are inferred from the claim text.